An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin

被引:40
作者
Lim, NK
Kim, JH
Oh, MS
Lee, S
Kim, SY
Kim, KS
Kang, HJ
Hong, HJ
Inn, KS
机构
[1] Aprogen Inc, Korea Res Inst Biosci & Biotechnol, Ctr Res & Dev, Bio Venture Ctr 311, Taejon 305333, South Korea
[2] Korea Res Inst Biosci & Biotechnol, Lab Antibody Engn, Taejon 305333, South Korea
关键词
D O I
10.1128/IAI.73.10.6547-6551.2005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lethal factor (LF) is a component of anthrax lethal toxin (LeTx). We generated anti-LF murine monoclonal antibodies (MAbs) that show LeTx-neutralizing activity in vitro and in vivo. Anti-LF MAbs were generated by immunization with recombinant LF, and the MAbs showing LeTx-neutralizing activity in vitro were selected. Two MAbs with the highest affinities, 5B13B1 (dissociation constant [K-d], 2.62 nM) and 3C16C3 (K-d, 8.18 nM), were shown to recognize the same or closely overlapping epitopes on domain III of LF. The 50% inhibitory concentration of 5B131B1 (0.21 mu g/ml) was approximately one-third that of 3C16C3 (0.63 mu g/ml) in the in vitro LeTx-neutralization assay. The 5B13B1 antibody, which had the highest neutralizing activity, provided perfect protection against LeTx challenge in an in vivo LeTx neutralization assay using Fisher 344 rats. In addition, the antibody showed pre- and postexposure prophylactic effects in the animal experiments. This is the first report that an MAb binding to domain III of LF has neutralizing activity against LeTx. The 5B13B1 antibody may be useful in prophylaxis against anthrax poisoning.
引用
收藏
页码:6547 / 6551
页数:5
相关论文
共 25 条
  • [1] Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin
    Agrawal, A
    Lingappa, J
    Leppla, SH
    Agrawal, S
    Jabbar, A
    Quinn, C
    Pulendran, B
    [J]. NATURE, 2003, 424 (6946) : 329 - 334
  • [2] Passive transfer of protection against Bacillus anthracis infection in a murine model
    Beedham, RJ
    Turnbull, PCB
    Williamson, ED
    [J]. VACCINE, 2001, 19 (31) : 4409 - 4416
  • [3] Identification of the cellular receptor for anthrax toxin
    Bradley, KA
    Mogridge, J
    Mourez, M
    Collier, RJ
    Young, JAT
    [J]. NATURE, 2001, 414 (6860) : 225 - 229
  • [4] Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies
    Brossier, F
    Lévy, M
    Landier, A
    Lafaye, P
    Mock, M
    [J]. INFECTION AND IMMUNITY, 2004, 72 (11) : 6313 - 6317
  • [5] Microbiology: A binding contract for anthrax
    Bull, JJ
    Parrish, CR
    [J]. SCIENCE, 2002, 297 (5579) : 201 - 202
  • [6] Cutting edge: Anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide
    Dang, O
    Navarro, L
    Anderson, K
    David, M
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (02) : 747 - 751
  • [7] Early Bacillus anthracis macrophage interactions:: intracellular survival and escape
    Dixon, TC
    Fadl, AA
    Koehler, TM
    Swanson, JA
    Hanna, PC
    [J]. CELLULAR MICROBIOLOGY, 2000, 2 (06) : 453 - 463
  • [8] Anthrax as a biological weapon, 2002 - Updated recommendations for management
    Inglesby, TV
    O'Toole, T
    Henderson, DA
    Bartlett, JG
    Ascher, MS
    Eitzen, E
    Friedlander, AM
    Gerberding, J
    Hauer, J
    Hughes, J
    McDade, J
    Osterholm, MT
    Parker, G
    Perl, TM
    Russell, PK
    Tonat, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (17): : 2236 - 2252
  • [9] Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis
    Karginov, VA
    Robinson, TM
    Riemenschneider, J
    Golding, B
    Kennedy, M
    Shiloach, J
    Alibek, K
    [J]. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2004, 40 (01): : 71 - 74
  • [10] Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization
    Kobiler, D
    Gozes, Y
    Rosenberg, H
    Marcus, D
    Reuveny, S
    Altboum, Z
    [J]. INFECTION AND IMMUNITY, 2002, 70 (02) : 544 - 550